Core Insights - Ginkgo Bioworks has been awarded a four-year contract worth up to $47 million by the Environmental Molecular Sciences Laboratory to develop a High-Throughput Automated Phenotyping Platform [1][5] - The platform aims to enhance the U.S. Department of Energy's capabilities in generating reproducible microbial data, thereby supporting the bioeconomy and biotechnology innovation [1][4] Group 1: Contract and Collaboration - The contract is part of a competitive procurement process and will support the Microbial Molecular Phenotyping Capability [1][5] - Ginkgo Automation will utilize its Catalyst scheduling software and modular Reconfigurable Automation Carts to automate workflows from media preparation to multimodal analytics [2][3] Group 2: Technological Features - The HTPAPP is designed to support BSL2 operations, remote planning, and laboratory integration, allowing for adaptability as scientific needs evolve [2][9] - Key features include a modular architecture, integrated transport, and software-enabled interleaving of diverse protocols to maximize efficiency [2][9] Group 3: Strategic Importance - The project aligns with the recent AI Action Plan aimed at boosting U.S. scientific innovation through AI-enabled cloud laboratories [4] - The platform is expected to increase throughput and reproducibility of phenotyping campaigns, capturing multimodal analytical measurements suitable for AI and machine learning applications [5][9] Group 4: Company Overview - Ginkgo Bioworks specializes in engineering biology, offering customizable R&D solutions across various sectors including therapeutics, diagnostics, and agriculture [8] - The company also provides laboratory automation solutions to enhance research efficiency and data generation for AI models [8]

Core Insights - Artisan Partners' "Artisan Small Cap Fund" reported strong performance in Q3 2025, with major US indices reaching record highs and the fund's Investor Class returning 8.69% [1] - Twist Bioscience Corporation (NASDAQ:TWST) was highlighted as a detractor in the fund's performance, with a one-month return of -20.34% and a 52-week loss of 37.05% [2][3] Fund Performance - The Artisan Small Cap Fund's Advisor Class fund returned 8.75%, and the Institutional Class fund returned 8.73%, while the Russell 2000 Growth Index returned 12.19% [1] - The fund's top 5 holdings were mentioned as key picks for 2025 [1] Company Analysis: Twist Bioscience Corporation - Twist Bioscience reported 18% revenue growth, driven by demand in next-generation sequencing, despite weaker sales in synthetic biology products [3] - The company has a market capitalization of $1.58 billion, with shares closing at $26.87 on November 14, 2025 [2] - The partnership with Veracyte is viewed as a validation of Twist's platform, potentially driving long-term upside [3] Hedge Fund Interest - Twist Bioscience was held by 23 hedge fund portfolios at the end of Q2 2025, a decrease from 30 in the previous quarter [4] - The company reported revenue of $99 million in Q4 2025, reflecting a 17% year-over-year growth [4]

Core Insights - Twist Bioscience (TWST) stock has experienced a significant decline of 10.1% in one day, raising concerns about potential deeper issues beyond temporary weakness [2] - The company is valued at $1.6 billion with a revenue of $362 million, and its stock is currently trading at $26.87 [2] - Revenue growth over the past year is reported at 22.7%, but the operating margin stands at -39.3% [2] - The stock is trading at a P/E multiple of -18.9 and a P/EBIT multiple of -9.5, indicating moderate operational performance and valuation, leading to it being considered fairly priced [3] Financial Position - The company has a debt-to-equity ratio of 0.05 and a cash-to-assets ratio of 0.39, suggesting a strong liquidity position [2] - TWST stock has historically underperformed compared to the S&P 500 during economic downturns, with a notable decline of 94.5% from its peak of $207.97 on January 20, 2021, to $11.49 on May 2, 2023 [7] - The stock has not yet returned to its pre-crisis high, with the highest price since then being $58.88 on July 23, 2024 [7] Market Performance - The stock dropped 43.9% from a high of $35.15 on March 6, 2020, to $19.71 on March 18, 2020, compared to a 33.9% decline for the S&P 500 [7] - In December 2018, TWST stock declined by 47.6% from a peak of $31.08 to $16.30, while the S&P 500 experienced a peak-to-trough decline of 19.8% [8] - Despite these declines, the stock has shown the ability to fully rebound to its pre-crisis peaks in previous instances [8]

Fiscal 2025 4Q and Full Year Financial Results N O V E M B E R 2 0 2 5 Agenda Welcome Angela Bitting SVP, Corporate Affairs Quarterly Highlights Emily Leproust Chief Executive Officer Business Highlights Patrick Finn President and Chief Operating Officer Financial and Operational Performance Adam Laponis Chief Financial Officer Milestones Emily Leproust Chief Executive Officer Q&A Session 2 | TWIST BIOSCIENCE | PROPRIETARY Legal Disclaimers This presentation contains forward-looking statements. All statemen ...

Core Insights - The event "Party Building Collaboration for Co-Creation" was held on October 31, involving multiple organizations to enhance early-stage scientific innovation through a strategic partnership [1] Group 1: Strategic Partnerships - Hongshan Capital, along with Hubei Hongshan Laboratory, Wuhan Venture Capital, Hongshan District Finance Bureau, and Lion Mountain Street, signed a cooperation agreement for a seed fund [1] - The collaboration aims to establish Hubei's first laboratory seed fund, focusing on modern agricultural fields such as biological breeding, synthetic biology, green production, and agricultural equipment [1] Group 2: Objectives and Goals - The initiative seeks to leverage the research, talent, and technological resources of Hubei Hongshan Laboratory to identify and cultivate high-quality technological achievements and early-stage projects [1] - The goal is to support the growth of regional technology enterprises and foster new productive forces in the area [1]

Core Insights - eXoZymes Inc. is a pioneer in AI-engineered enzymes that convert sustainable feedstock into nutraceuticals, medicines, and essential chemicals [1] - CEO Michael Heltzen will present at the 2025 ThinkEquity Conference on October 30, 2025, in New York City [1] - Heltzen highlighted that synthetic biology has not scaled commercially despite significant investment, indicating a gap between investment and tangible results [1] Company Overview - eXoZymes focuses on the development of AI-engineered enzymes [1] - The company aims to transform sustainable feedstock into various essential products [1] Industry Context - The synthetic biology sector has faced challenges in achieving commercial scalability [1] - There is a notable disparity between the amount of investment in synthetic biology and the outcomes produced [1]

Core Insights - Conestoga Capital Advisors reported that equity markets reached new all-time highs in Q3 2025, with the Conestoga Micro-Cap Composite returning 11.7% net-of-fees, while the Russell Microcap Growth Index returned 19.9% [1] Company Overview: Twist Bioscience Corporation - Twist Bioscience Corporation (NASDAQ:TWST) specializes in manufacturing and distributing synthetic DNA-based products, with a one-month return of 23.58% and a 52-week loss of 18.74% [2][3] - As of October 21, 2025, Twist Bioscience's stock closed at $33.39 per share, with a market capitalization of $2.015 billion [2] Financial Performance - In Q3 2025, Twist Bioscience reported revenue of $96.1 million, reflecting an 18% year-over-year growth and approximately 4% sequential growth [4] - The company faced challenges due to softened demand for synthetic DNA products in biotech and academic research markets, leading to slowed order growth amid tighter biopharma funding [3][4] Market Position and Investment Sentiment - Twist Bioscience was held by 23 hedge fund portfolios at the end of Q2 2025, a decrease from 30 in the previous quarter [4] - Despite the long-term growth potential in genomics and DNA data storage, concerns about cash burn and valuation compression across synthetic biology peers have impacted investor sentiment [3][4]

Industry Overview - Genomics is a comprehensive study of genomes, focusing on understanding gene functions and interactions within organisms and their environments [1][2] - The field of genomics is gaining traction among pharmaceutical and biotechnology companies due to recent breakthroughs and the potential for personalized medicine [2][4] Market Potential - The genomics market is projected to reach $80.17 billion by 2032, while the synthetic biology market was valued at $16.2 billion in 2024 and is expected to grow at a CAGR of 17.30% from 2025 to 2030 [7] Key Companies GeneDx Holdings Corp. - GeneDx is a leading genomics company specializing in exome and genome tests, which surged 69% year-over-year to $85.9 million in Q2 2025, with test volume increasing by 28% [10] - The company acquired Fabric Genomics in May 2025 to enhance genomic diagnostics through AI-powered interpretation services [11][12] - GeneDx currently holds a Zacks Rank 1 (Strong Buy) [12] Twist Biosciences - Twist Biosciences has developed a DNA synthesis platform for engineering biology, producing synthetic DNA products for various applications, including drug discovery [13][14] - The company has expanded its offerings to include synthetic RNA and antibody proteins, catering to biotech, pharma, and industrial sectors [14][15] - Twist Biosciences holds a Zacks Rank 3 (Hold) [15] Wave Life Sciences - Wave Life Sciences focuses on RNA medicines, utilizing its PRISM platform to develop treatments for both rare and common disorders [16] - The company has a diverse pipeline targeting conditions such as obesity, AATD, DMD, and HD, with its first siRNA candidate, WVE-007, entering clinical development [17][18] - Wave Life Sciences ended Q2 with cash and equivalents of $208.5 million, sufficient to fund operations into 2027, and holds a Zacks Rank 3 [19]

Core Insights - Twist Bioscience Corp. (NASDAQ:TWST) is recognized as a leading emerging technology stock, specializing in synthetic DNA manufacturing through a silicon-based synthesis platform, which offers scalable production with high accuracy and affordability compared to traditional methods [1][6] Company Performance - TD Cowen analyst Brendan Smith reaffirmed a Buy rating on Twist Bioscience with a price target of $36 following the company's presentation at the Baird Global Healthcare Conference 2025, where management discussed advancements in profitability and operational efficiency [3] - The company reported gross margins exceeding 50%, indicating effective scaling and disciplined execution, with a goal to achieve adjusted EBITDA breakeven by fiscal 2026 [4] - Management noted that each additional dollar of revenue contributes approximately $0.75 to $0.80 to gross margin [4] Growth Opportunities - Management identified several growth levers, including the expansion of the MRD opportunity, customer migration from microarrays to Twist's sequencing solutions, and further integration of synthetic biology with biopharma [5] - Despite the growth potential, challenges such as a tough funding environment and the need to balance cost discipline with innovation were acknowledged [5] Industry Context - The platform developed by Twist Bioscience has applications in various sectors, including drug discovery, diagnostics, agriculture, and data storage, positioning the company as a frontrunner in the commercial potential of synthetic biology [2]

Core Insights - Jinan City is implementing an "Industrial Strong City Development Strategy" with a focus on high-tech zones and 11 key industrial chains [1][3] - The High-tech Zone is adopting a "one chain, one policy" approach to strengthen its leading industries and promote future industrial growth [3] Industry Developments - The High-tech Zone has established a Future Industry Alliance to promote innovative applications in artificial intelligence, aerospace information, and humanoid robotics [3] - The quantum information industry has achieved comprehensive layout in communication, measurement, and computing, being recognized as a future industrial cluster in Shandong Province [3] - The aerospace information industry is forming clusters across multiple fields, enhancing its overall competitiveness [3] - The core artificial intelligence industry accounts for over 60% of the city's total, with more than 280 related enterprises concentrated in the area [3] - The cell and gene industry is leading with several domestic and international records for being the "largest" and "earliest" in various achievements [3] - Significant advancements have been made in next-generation industrial software, new energy storage, and synthetic biology, indicating a diversified growth strategy [3]